Never Run Out Of Buyers To Sell To.

Bioheng is rebranding to Imviva Biotech to better reflect our global positioning and expansion. Bioheng Therapeutics is a clinical-stage company focused on allogeneic "off-the-shelf" universal CAR-T therapies. Founded in 2017, we aim to develop the world’s leading allogeneic cell therapy platforms and products to address some of the most challenging unmet needs. In February 2025, our CD7-targeted UCAR-T, CTD402, received Investigational New Drug (IND) approval from the U.S. FDA for the treatment of T-ALL/LBL.This product is based on Bioheng's novel and proprietary UCAR-T technology platform -…
Annual Revenue$50M to $100M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.